News

May 17, 2023

Tara Franks, Chief Operating Officer of TD2, recognized as a 2023 Phoenix Titan 100

SCOTTSDALE, ARIZONA, UNITED STATES, May 17, 2023 / EINPresswire.com/ -- Titan CEO and headline sponsor Wipfli LLP are pleased to announce Tara Franks, Chief Operating Officer of Translational Drug Development (TD2), as a 2023 Phoenix Titan 100. The Titan 100...

April 11, 2023

TD2 to Highlight the Development of a Novel Metabolomic Cancer Model at the AACR Annual Meeting 2023

SCOTTSDALE, ARIZONA, UNITED STATES, April 11, 2023/EINPresswire.com/ -- Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of their preclinical development of a novel Diet-Induced Obesity Model for antitumor, proteomic, and metabolomic studies at the...

October 05, 2022

TD2 Announces Dr. Alan Miller as New Chief Medical Officer

The respected Medical Oncology leader brings extensive experience as TD2 continues its strategic growth. SCOTTSDALE, ARIZONA, UNITED STATES, October 5, 2022 /EINPresswire.com/ -- Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the addition of Dr. Alan...

August 25, 2022

SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line

NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...

August 09, 2022

SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) – SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...

May 12, 2022

Genzada Pharmaceuticals Opens Phase 1B Metastatic Breast Cancer Trial

HUTCHINSON, Kan. – May 12, 2022 – Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Pharmaceuticals SA, announced today the official opening of a Phase 1B clinical trial for the oral therapeutic GZ17-6.02 (6.02) in combination with capecitabine in...

April 05, 2022

TD2 to Highlight Preclinical Progress of Two Novel HDAC Inhibitors at AACR Annual Meeting

SCOTTSDALE, ARIZONA, UNITED STATES, April 5, 2022 /EINPresswire.com/ -- Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of the preclinical results of two novel, targeted epigenetic inhibitors at the American Association for Cancer Research...

March 30, 2022

Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302

CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it...

October 14, 2021

TD2 Partners with Medidata to Enhance its Clinical Operations and Accelerate Clinical Trials

Medidata, a Dassault Systèmes company, today announced that Translational Drug Development (TD2), a precision oncology contract research organization (CRO), has signed an agreement to adopt Medidata’s Rave CTMS (Clinical Trial Management System) and eTMF (electronic Trial Master File) solutions. Rave CTMS and eTMF are...

September 16, 2021

TD2 and Deep Lens Partner to Enable Diversity, Access and Faster Clinical Trial Enrollment for Community Oncology Practices

Key Partnership Will Connect Patients with Precision Oncology Clinical Trials and Novel Therapies, Accelerating Access to Promising Treatments Translational Drug Development (TD2), a leading precision oncology contract research organization (CRO), and Deep Lens have announced a strategic partnership that will...

Load More

Events

April 16, 2023

AACR 2023

Orlando, FL | Orange County Convention Center

Learn more +

June 2, 2023

2023 ASCO Annual Meeting

Chicago, IL | McCormick Place Convention Center

Learn more +

June 7, 2023

SCRS West Coast Clinical Tech & Innovation Summit

The Scott Resort & Spa | Scottsdale, AZ

Learn more +

July 12, 2023

11th Annual Tumor Models Boston

Westin Boston Seaport | Boston, MA

Learn more +

STAY IN TOUCH

Get free tips, tools and resources by subscribing to the TD2 newsletter.

Skip to content